Alcavis HDC, LLC – Trademark Portfolio

Entity Type: 16

Alcavis HDC, LLC holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include MAKY, EXSEPT, ALCAVIS, PERACHEK, and PERACIDIN. The owner is based in Gaithersburg, MD.

8322 Helgerman Court

Gaithersburg, MD 208774103

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Alcavis HDC, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Alcavis HDC, LLC have?

Alcavis HDC, LLC has 10 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 cancelled.

What trademark classes does Alcavis HDC, LLC file in?

Alcavis HDC, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Alcavis HDC, LLC's most well-known trademarks?

Alcavis HDC, LLC's registered trademark portfolio includes well-known marks such as MAKY, EXSEPT, ALCAVIS, PERACHEK, and PERACIDIN. These are among 8 currently registered trademarks in the portfolio.

What is Alcavis HDC, LLC's trademark registration success rate?

Alcavis HDC, LLC has a 80% trademark registration rate, with 8 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.